A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04305184
- Locations
- 🇺🇸
Charlotte ENT Associates, Matthews, North Carolina, United States
🇺🇸Breathe Clear Institute, Torrance, California, United States
🇺🇸Stanford Hospital, Palo Alto, California, United States
A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants
- Conditions
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04277624
- Locations
- 🇺🇸
PAREXEL Early Phase Clinical Unit, Baltimore, Maryland, United States
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT04240002
- Locations
- 🇩🇪
Site DE49001, Halle (Saale), Sachsen-Anhalt, Germany
🇮🇹SIte IT39001, Roma, Italy
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT04225117
- Locations
- 🇯🇵
Site JP81004, Nagoya, Aichi, Japan
🇯🇵Site JP81001, Kashiwa, Chiba, Japan
🇯🇵Site JP81005, Chuo-ku, Osaka, Japan
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1030
- Registration Number
- NCT04223856
- Locations
- 🇺🇸
Hillman Cancer Center / University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇯🇵Site JP81006, Kawasaki-shi, Japan
🇨🇳Site CN86025, Hefei, China
A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites
- Conditions
- Interventions
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04184895
- Locations
- 🇩🇪
Site DE49001, Berlin, Germany
🇩🇪Site DE49002, Hannover, Germany
An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT04136808
- Locations
- 🇺🇸
UCLA Hematology Oncology, Los Angeles, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Northwestern University Medical Center, Chicago, Illinois, United States
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04096157
- Locations
- 🇺🇸
Parexel International, Baltimore, Maryland, United States
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04094519
- Locations
- 🇲🇩
Site MD37301, Chisinau, Moldova, Republic of
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT04079296
- Locations
- 🇺🇸
Memorial Healthcare System-West, Pembroke Pines, Florida, United States
🇺🇸City of Hope, Duarte, California, United States
🇯🇵Site JP81005, Nagoya, Aichi, Japan